Lipodystrophy Project CGT2 – Milestones


  • In-licensing of the project from Lipigon.


  • Design of expression plasmids, which are a starting material for gene-therapeutic vectors CombiGene intends to develop for treatment of partial lipodystrophy.
  • In vitro studies (tests on liver cells) show proper protein expression.
  • Priority-based patent application filed with the UK Patent Office.
  • In vivo studies initiated for evaluation of the different gene therapy vectors.


  • The lipodystrophy projects receive EUR 882 500 in development grants from the EU Eurostars program.

CombiGene s project CGT2 is supported by the Eurostars Programme.Project ID: 114714

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99



CombiGene AB, Agavägen 52A, SE-181 55 Lidingö


Linked In     Twitter      Facebook